BBIO — BridgeBio Pharma Income Statement
0.000.00%
Last trade - 00:00- $13.51bn
- $15.64bn
- $502.08m
Annual income statement for BridgeBio Pharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 69.7 | 77.6 | 9.3 | 222 | 502 |
| Cost of Revenue | |||||
| Gross Profit | 66.6 | 74.2 | 6.86 | 218 | 481 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 646 | 590 | 617 | 663 | 1,047 |
| Operating Profit | -577 | -512 | -607 | -441 | -545 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -586 | -485 | -653 | -542 | -733 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -586 | -485 | -653 | -543 | -733 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -563 | -481 | -643 | -536 | -725 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -563 | -481 | -643 | -536 | -725 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -3.9 | -2.97 | -3.9 | -3.35 | -3.64 |